Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

Inclusion Criteria: * Evidence of Hyperplasia with Masood score of 13 or higher and 500 or more epithelial cells on cytology slide of screening Random Periareolar Fine Needle Aspiration (RPFNA) * Access to smart phone and or computer * Willing to comply with diet, exercise and lifestyle modification during weight reduction and maintenance phase. * Willing to start the dietary and exercise intervention within 9 months of RPFNA * Willing to complete quality of life questionnaires at multiple visits * Willing to have a medical history and physical at multiple visits * Willing to have an additional RPFNA at two additional visits * Be willing to have blood drawn at multiple visits * Willing to sign and able to understand consent for the RPFNA's and study participation * Reasonable hematopoetic, kidney and liver function consistent with safe participation on this trial. Exclusion Criteria: * Having taken medications that seriously affect metabolism such as steroids, dexatrim or other diet drugs within 3 weeks of study registration * Have changed dose or type of hormone supplementation within 3 months * Currently receiving other investigational agents * Have been on a chemoprevention trial within 6 months or taken a Selective Estrogen Receptor Modulator or aromatase inhibitor within last 6 months. * Need for chronic use of aspirin, nonsteroidal anti-inflamatory drug (NSAID) or other anti-inflammatory agents * Taking metformin, or other diabetes medications * Taking statins * Unable to participate in moderate intensity exercise (walking, treadmill, elliptical, water aerobics) * Would be unable to participate, by phone, in weekly phone call sessions * Cells suspicious for malignancy as assessed by cytotechnologist or cytopathologist.